UK Markets closed

Global Idiopathic Pulmonary Fibrosis Market – Analysis By Drug Type, End User, By Region, By Country : Market Insights, Pipeline and Forecast with Impact of COVID-19

·3-min read

Executive Summary According to the report, the global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271. 3 Million in the year 2020 with North America leading the regional market share.

New York, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Idiopathic Pulmonary Fibrosis Market – Analysis By Drug Type, End User, By Region, By Country : Market Insights, Pipeline and Forecast with Impact of COVID-19" - https://www.reportlinker.com/p06195732/?utm_source=GNW


The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant’s were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.

The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes are considered the most common cause for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favouring the growth of the market.

Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market.

Moreover, to pharmacological treatments, various non-pharmacological treatments are also used for IPF patients. The most used non-pharmacological treatments are lung transplantations, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation. In general, the treatment approach in IPF is largely dependent on a patient’s symptoms, the stage of the disease, and a patient’s overall health.

Scope of the Report
• The report presents the analysis of the Idiopathic Pulmonary Fibrosis market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone, Others).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by End User (Hospital & Clinics, Academic and Research Organizations, Others).

• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Region (North America, Europe, Asia Pacific).

• The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).

• The attractiveness of the market has been presented by region, by Drug Class and by End User.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

• The companies analysed in the report include AbbVie Inc., Bristol-Myers Squibb, F. Hoffman-La Roche, Ltd., Boehringer Ingelheim, Merck KGaA, Gilead Sciences, Liminal Biosciences, Cipla, Galapagos NV, FibroGen, Medicinova Inc.

Key Target Audience

• Pharmaceutical and Healthcare Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities
Read the full report: https://www.reportlinker.com/p06195732/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting